Epigenomics Financials
| EPGNF Stock | USD 0.50 2.00 80.00% |
Epigenomics |
Understanding current and past Epigenomics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Epigenomics' financial statements are interrelated, with each one affecting the others. For example, an increase in Epigenomics' assets may result in an increase in income on the income statement.
The data published in Epigenomics' official financial statements usually reflect Epigenomics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Epigenomics AG. For example, before you start analyzing numbers published by Epigenomics accountants, it's critical to develop an understanding of what Epigenomics' liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Epigenomics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Epigenomics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Epigenomics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Epigenomics AG. Please utilize our Beneish M Score to check the likelihood of Epigenomics' management manipulating its earnings.
Epigenomics Stock Summary
Epigenomics competes with Sotera Health, Neogen, Qiagen NV, Burning Rock, and Guardant Health. Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany. Epigenomics operates under Diagnostics Research classification in the United States and is traded on OTC Exchange. It employs 36 people.| Instrument | USA Pink Sheet View All |
| Exchange | PINK Exchange |
| Business Address | Geneststrasse 5, Berlin, |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Benchmark | NYSE Composite |
| Website | www.epigenomics.com |
| Phone | 49 30 243 450 |
| Currency | USD - US Dollar |
You should never invest in Epigenomics without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Epigenomics Pink Sheet, because this is throwing your money away. Analyzing the key information contained in Epigenomics' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Epigenomics Key Financial Ratios
Generally speaking, Epigenomics' financial ratios allow both analysts and investors to convert raw data from Epigenomics' financial statements into concise, actionable information that can be used to evaluate the performance of Epigenomics over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Epigenomics AG reports annually and quarterly.Epigenomics Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Epigenomics's current stock value. Our valuation model uses many indicators to compare Epigenomics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Epigenomics competition to find correlations between indicators driving Epigenomics's intrinsic value. More Info.Epigenomics AG is one of the top stocks in return on equity category among related companies. It is one of the top stocks in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Epigenomics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Epigenomics' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Epigenomics' earnings, one of the primary drivers of an investment's value.Epigenomics AG Systematic Risk
Epigenomics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Epigenomics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Epigenomics AG correlated with the market. If Beta is less than 0 Epigenomics generally moves in the opposite direction as compared to the market. If Epigenomics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Epigenomics AG is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Epigenomics is generally in the same direction as the market. If Beta > 1 Epigenomics moves generally in the same direction as, but more than the movement of the benchmark.
About Epigenomics Financials
What exactly are Epigenomics Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Epigenomics' income statement, its balance sheet, and the statement of cash flows. Potential Epigenomics investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Epigenomics investors may use each financial statement separately, they are all related. The changes in Epigenomics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Epigenomics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.Steps to analyze Epigenomics Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Epigenomics is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Epigenomics has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Epigenomics' financials are consistent with your investment objective using the following steps:- Review Epigenomics' balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand Epigenomics' liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare Epigenomics' financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Epigenomics' stock is overvalued or undervalued.
Epigenomics April 25, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Epigenomics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Epigenomics AG. We use our internally-developed statistical techniques to arrive at the intrinsic value of Epigenomics AG based on widely used predictive technical indicators. In general, we focus on analyzing Epigenomics Pink Sheet price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Epigenomics's daily price indicators and compare them against related drivers.
| Information Ratio | 0.14 | |||
| Maximum Drawdown | 480.0 |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Epigenomics AG. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Complementary Tools for Epigenomics Pink Sheet analysis
When running Epigenomics' price analysis, check to measure Epigenomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Epigenomics is operating at the current time. Most of Epigenomics' value examination focuses on studying past and present price action to predict the probability of Epigenomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Epigenomics' price. Additionally, you may evaluate how the addition of Epigenomics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |